Absstract of: WO2023038858A1

The methods and composition described herein can improve outcomes for COVID-19 patients. The methods identify patients who will suffer from severe COVID-19 by a protein signature that can be detected five to seven days prior to the onset of severe COVID-19 symptoms. The patients with the severe COVID-19 signature can begin ameliorative therapies prior to the onset of severe COVID-19 symptoms.

Absstract of: WO2023039442A1

The present disclosure provides antibody combinations and related methods for treating a SARS-CoV-2 infection in a subject or for manufacturing a medicament for the treatment of a SARS-CoV-2 infection. In some aspects, therapy comprises two antibodies that bind compete for binding to a SARS-CoV-2 surface (S) glycoprotein monomer. The antibody combinations can potently neutralize SARS-CoV-2, can broadly neutralize SARS-CoV-2 variants, and are resistant to viral breakthrough. Antibody compositions comprising such combinations are also provided.

Absstract of: WO2023038815A1

Disclosed herein is method for treating and/or preventing a cytokine release-related condition associated with infection by a respiratory virus, e.g., COVID-19 or influenza. In certain embodiments, the method may comprise administering a compound that inhibits Interleukin Receptor-Associated Kinase (IRAK) to a subject experiencing, or at risk of developing, the condition. In some embodiments, the compound may have a structure according to Formulas IV or VII, or a salt, solvate, N-oxide and/or prodrug thereof.

Absstract of: WO2023036191A1

A vaccine for a novel coronavirus SARS-CoV-2 Delta variant and an application, the vaccine comprising a fusion protein, and the fusion protein comprising: (1) an interferon or a functional fragment thereof; (2) a novel coronavirus SARS-CoV-2 delta strain S protein or a functional fragment thereof; and (3) an immunoglobulin Fc region. The vaccine can improve the immunogenicity and neutralizing antibody titer for mutant novel coronavirus antigens by means of the fusion-expressed IFN; it ensures efficient production of neutralizing antibodies, and can significantly improve the defense against mutant strains.

Absstract of: WO2023036152A1

A detection method and kit for SARS-Cov-2. The detection kit for SARS-Cov-2 comprises a first group of antibodies and a second group of antibodies for detecting SARS-Cov-2 from a sample of a subject; the first group of antibodies comprises an antibody 1 selected from antibodies binding to N protein amino acid fragments 44-180 of SARS-Cov-2; the second group of antibodies comprises an antibody 2 selected from antibodies binding to N protein amino acid fragments 44-180 of SARS-Cov-2; and the antibody 1 and the antibody 2 can be the same antibody or different antibodies. The detection method and kit can improve the detection sensitivity and the detection rate, and in particular can detect variants of COVID-19.

Absstract of: WO2023036153A1

A new coronavirus antibody and the use thereof. The antibody binds to an amino acid fragment at the 44-180th site of the SARS-CoV-2 nucleocapsid protein, but does not bind to the amino acid fragment at the 44-84th site, the amino acid fragment at the 65-103th site, the amino acid fragment at the 96-136th site, and the amino acid fragment at the 130-180th site.

Absstract of: AU2022218604A1

Abstract: A technique for treating viruses; like COVID-19 and their variants and any other respiratory virus, bacteria or fungus that already known or will be discovered later, which attack the respiratory system starting from the nose ending with the deep inner side of any living creature lungs. It is easy to treat the viral infection in the upper part of the respiratory system or outer parts of the body with gargling by salt, povidone-iodine and alcohol diluted solutions or 100% Alcohol or other disinfectant solutions, which are very efficient to kill the viruses on the spot. What we are looking for is a way to get into the lungs directly, fast and efficient enough before the failure of the lungs, which is the main reason that leads to death. This technique provides the patent with a treatment using safe disinfectant solutions like salt solution, povidone-iodine and alcohol diluted solutions or alcohol liquid through a device that enables the patient to inhale the air which goes through the treatment liquid and becomes a carrier of the same properties of the disinfectant. The device is portable or fixed depending on the size and can operate manually or electrically as it depends on pulling the air by the mouth or by heating the liquid or injecting the air by compressing or pumping the air into the device. In the present invention, the apparatus consists of several forms, some of them are for cold or vaporous liquids others are for hot liquids Figure 1 Figure 2 Page 1 of 5

Absstract of: AU2022221464A1

Abstract The present invention is directed to a compound herbal composition for treatment of or prevention of COVID-19 or other viral infections, and/or treatment of or prevention of one or more of medical conditions resulting from COVID-19, comprising: Angelica dahurica, Elsholtzia splendens, Lonicera japonica, Glycine max, Siraitia grosvenorii, Zingiber officinale, Platycodon grandifloras, Imperata cylindrica, Phragmites australis, Allium cepa, Glycyrrhiza uralensis, and Prunus persica. Further herbal extracts can also be added to this base composition, including Tetradium ruticarpum, Alpinia oxyphylla, Cullen corylifolium, Cornus officinalis, Scutellaria baicalensis, Forsythia suspensa, Dolichos lablab, Coix lachryma-jobi, Agastache rugosa, Myristica fragrans, Cinnamomum cassia, Zingiber officinale, Foeniculum vulgare, Zanthoxylum bungeanum, Astragalus membranaceus, Chrysanthemum indicum, Taraxacum mongolicum, Viola yedoensis, Begonia fimbristipula, Scaphium scaphigerum, Houttuynia cordata, Gardenia jasminoides, Nelumbo nucifera, Lophatherum gracile, Dioscorea oppositifolia, Amomum villosum, Cornus officinalis and Euryale ferox.

Absstract of: AU2021313476A1

The present invention provides pharmaceutical compositions and methods of treating Covid-19 infectious disease. The present invention also provides pharmaceutical compositions and methods of prophylaxis or prophylactic treatment of Covid-19 infectious disease. The said methods involve administering compositions comprising therapeutically effective amount of Cannabidiol thereby causing enhancement / augmentation of innate immunity of the patient / mammal/human due to at least one of the following effects, i) infected patient cells undergo apoptosis early after infection; ii) induction of interferon transcription in the patient; iii) induction of interferon-induced antiviral effectors in the patient.

Absstract of: US2023081767A1

A method is described for producing a vaccine from a neutered pathogenic source. The neutered pathogenic source may be a SARS-COV-2 virus that is neutered with a defined dose of UV-C light. The neutered SARS-COV-2 viral vaccine is administered through an inhalation pump.

Absstract of: US2023082323A1

Disclosed herein are methods, complexes, kits, systems and algorithms for detecting or determining an amount, quantity, concentration and/or level of at least one type of anti-β-coronavirus antibody, such as, for example, an anti-SARS-CoV antibody or anti-SARS-CoV-2 antibody (including an IgA, IgG and/or an IgM antibody), in one or more samples obtained from a subject.

Absstract of: US2023082096A1

Disclosed are nucleic acid oligomers, including amplification oligomers and detection probes, for amplification and/or detection of human coronavirus OC43,HKU1, NL63, and/or 229E nucleic acid. Also disclosed are methods of nucleic acid amplification and/or detection using the disclosed oligomers, as well as corresponding reaction mixtures and kits.

Absstract of: US2023080695A1

The present invention relates to a composition comprising lactoferrin for oral use as an antiviral, preferably for use in the treatment of viral infections of the respiratory system and of symptoms or disorders deriving from, or relating to, said viral infections, preferably SARS-coronavirus viral infections (e.g. COVID-19).

Absstract of: US2023080694A1

Disclosed in the present invention is a Helicobacter pylori ferritin-based novel coronavirus S protein double-region subunit nanovaccine. According to the present invention, both a receptor binding domain (RBD) and a fusion peptide (FP) of a virus are taken as double antigens and are connected with a Helicobacter pylori multimeric protein (HP_Ferritin) to form a fusion protein RBD-FP-HP_Ferritin, so that antigen multimerization is realized; and an eukaryotic cell expression system is then utilized for expression, so as to form a 24-mer nano-antigen by means of the self-assembly action of the HP_Ferritin. According to the solution, the defect that RBD monomers are insufficient in immunogenicity can be overcome; the obtained vaccine can remarkably improve the level of neutralizing antibodies of a host to viruses; and the generated antibodies have the capacity to strongly prevent the viruses from invading target cells.

Absstract of: US2023078211A1

A decontamination system includes a housing having at least one inner surface defining a chamber. An irradiation system supplies ultraviolet germicidal irradiation (UVGI) to the chamber at a level effective to at least one of inactivate SARS-CoV-2 or inactivate at least 90% single-stranded RNA viruses present on an object positioned in the chamber in less than about 2 minutes.

Absstract of: US2023081431A1

A group of known compounds has been found to have polymerase inhibitor qualities and are presumed to be efficacious in the protection of human cells from damage by the SARS-CoV-2 virus, which causes the COVID-19 disease. These compounds, referred to herein as Special Phenyl Compounds, provide such protection by inhibiting replication of the virus, which is done by interfering with its RNA transcription process. These compounds can also be used to treat diseases caused by structurally related viruses such as West Nile virus, Marburg virus, Ebola virus, dengue virus, HIV, hepatitis C virus (HepC), and coronaviruses other than SARS-CoV2. Patients are treated by administering effective doses of one or more of the compounds.

Absstract of: US2023077887A1

The present disclosure discloses a detection kit and a preparation method thereof and a detection method for novel coronavirus, and relates to the technical field of biomedicine, including an antigen test strip. The antigen test strip includes a substrate, bibulous paper, immune nitrocellulose membrane, and immune microsphere pad. The immune microsphere pad, the immune nitrocellulose membrane and the bibulous paper are pasted on the substrate. The The immune microsphere pad is coated with latex microsphere-labeled novel coronavirus SARS-CoV-2 monoclonal antibody 1. The immune nitrocellulose membrane is provided with a test line coated with novel coronavirus SARS-CoV-2 monoclonal antibody 2 and a quality control line coated with goat anti-mouse IgG polyclonal antibody. The present disclosure uses latex particles as labeled tracer, and uses antigen-antibody reaction and lateral chromatography to detect and analyze targets, having advantages of convenience and swift.

Absstract of: US2023077704A1

Nitazoxanide represented by formula I and an active form thereof, tizoxanide compound, represented by formula II, a geometric isomer thereof and pharmaceutically acceptable salt thereof and/or solvate thereof and/or hydrate thereof, and a pharmaceutical composition containing this compound, used for preventing and/or treating coronavirus (such as SARS-CoV-2) infection.

Absstract of: US2023081837A1

In alternative embodiments, provided are pharmaceutical compositions comprising combinations of drugs, including products of manufacture and kits, and methods for using them, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, combinations, or cocktails, of a drug or drugs as provided herein are administered either enterally, parenterally and/or by inhalation. In alternative embodiments, combinations, or cocktails, of drugs as provided herein are used to block intracellular metabolic pathways and prevent progression of the infection to clinical illness and death. In alternative embodiments, novel aerosol, spray or mist or powder formulations for inhalation are provided. In alternative embodiments, provided are therapeutic combinations of drugs or a drug, a pharmaceutical dosage form, a drug delivery device, or a product of manufacture, comprising: opaganib or YELIVA™, or opaganib or YELIVA™ and oral and/or inhaled chloroquine (or ARALEN™) chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (optionally, PLAQUENIL™), with or without azithromycin, wherein optionally each or all of the opaganib, the chloroquine (or ARALEN™), ch

Absstract of: US2023081039A1

The present application relates to a pharmaceutical composition comprising polynucleotides and use thereof for prevention or treatment of COVID-19. More specifically, disclosed in the present application is a composition used for prevention or treatment of COVID-19, comprising a polyriboinosinic-polyribocytidylic acid, an antibiotic or polyamino compound, a positive ion, and an optional antigen derived from novel coronavirus SARS-CoV-2. Also provided is use of the composition in preparation of a drug or vaccine for prevention or treatment of novel coronavirus SARS-CoV-2.

Absstract of: US2023084300A1

The present invention relates to the use of an immunomodulator comprising non-pathogenic non-viable Mycobacterium, such as Mycobacterium obuense (IMM-101), and one or more biologically-active agents, suitably an antigen or antigenic determinant, in a method of treating or preventing a infection and/or the symptoms associated thereof in a human subject at elevated risk of exposure to and/or severity of said infection, such as a healthcare or social care worker or cancer patient, wherein said viral infections are preferably caused by a coronavirus. The invention is particularly applicable to those infections caused by SARS-CoV, MERS-CoV, or SARS-CoV-2 (COVID-19). The invention also provides an adjuvant and pharmaceutical composition comprising said immunomodulator optionally with a pharmaceutically acceptable carrier, diluent or excipient, as well as the use of said adjuvant or said pharmaceutical composition in the manufacture of a medicament for the treatment or preventions of said infections.

Absstract of: US2023084035A1

Provided herein are methods for reducing risk of severe symptoms and outcomes associated with Coronavirus Disease 2019 (COVID-19) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection by measuring levels of interleukin 6 (IL-6), IL-8, IL-22, and serum ferritin in a subject. Also provided are methods for treating a subject exposed to or at elevated risk of expose to SARS-CoV-2 based on levels of IL-6, IL-8, IL-22, and ferritin in the serum of the subject.

Absstract of: US2023085607A1

Disclosed are novel mechanisms of action of ivermectin therapy as related to treatment of COVID-19 and means of augmenting therapeutic activities by co-administration with one or more of the following: pterostilbene, thymoquinone, epigallocatechin-3-gallate, and sulforaphane. In one embodiment the invention provides enhanced reduction of inflammation induced pulmonary leakage without augmenting immune suppressive mechanisms.

Absstract of: US2023082992A1

The invention provides the use of a formulation containing cyclodextrine, quercetin and zinc, at appropriate concentrations to mitigate infections by enveloped viruses like SARS-CoV-2, influenza and HIV/AIDS, when administered via pulmonary and dermal route. While the different forms of cyclodextrin prevent the entry of coated virus into host cells by extracting and sequestering cholesterol molecules at the virus coat and at the host cell plasma membrane, the natural plant-based ionophore quercetin in the formulation, enables cellular entry of zinc, inhibiting viral replication by altering polymerase activity in the host cell. Hence cyclodextrine, and quercetin plus zinc, either in combination or in tandem order of administration, serves both as prophylactic and therapeutic.

Absstract of: US2023080265A1

The present disclosure relates to genetically modified non-human animals (e.g., genetically-modified mice or rodents) that express a hACE2 and/or hTMPRRS2 under control of the mouse promoter and the genetically modified non-human animal does not express native ACE2 and/or hTMPRRS2. The present disclosure also relates to methods of generating the genetically-modified animals (e.g., genetically modified mice or rodents), and methods of using the genetically modified non-human animals (e.g., genetically modified mice or rodents) described herein.